Non-Metastatic Triple-Negative Breast Cancer Patient Survival Analysis

A retrospective study of 149 patients with non-metastatic triple-negative breast cancer diagnosed between 2014 and 2020. The data assesses androgen receptor expression and its correlation with clinical outcomes, including 5-year overall survival, disease-free survival, and breast cancer-specific survival rates. The study was authored by Mahmoud Al-Masri.

Use Cases

• Analyze the association between androgen receptor expression status and 5-year overall survival rates in 149 patients.
• Correlate androgen receptor status with disease-free survival and breast cancer-specific survival metrics from clinical follow-up.
• Perform survival analysis using hazard ratios from univariable and multivariable analyses for overall and disease-free survival.

Strengths

• Contains clinical outcome data for 149 patients, a specific cohort size for analysis.
• Includes long-term follow-up survival data spanning up to 103 months.
• Provides specific statistical results, including 5-year OS rates of 60% and 70% for AR-negative and AR-positive groups.

Limitations

• The dataset is small, with only 149 patient records, limiting statistical power for subgroup analyses.
• Data is presented in a DOCX document, requiring manual extraction for computational analysis.
• The study's conclusion indicates AR status showed no significant prognostic association, limiting predictive modeling potential.

Provenance

Source

figshare

Collection Method

Retrospective comparative study using immunohistochemical staining on archived tissue samples.

Time Range

2014-2020

Freshness

null

Geography

null